The company hopes to develop saliva-based RNA assays for concussion, Parkinson's disease and autism using biomarkers discovered by its two academic partners.
Using large-scale GWAS data, researchers saw shared genetic contributors for ALS and frontotemporal dementia, as well as ALS and progressive supranuclear palsy.
Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.
The group will work with hospitals to recruit patients with a genetic history of Parkinson's to test for mutations in LRRK2 and GBA, as well as offer genetic counseling.
The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.
Two studies appearing in JAMA Neurology respectively examined how variants linked to Alzheimer's disease and Parkinson's disease contribute to the conditions.
In Science this week: mutations that allow the malaria parasite to evade treatment, and more.
New research suggests that some risky and protective variants in the LRRK2 gene have shared genetic effects in Crohn's disease and Parkinson's disease.
The partners will integrate genomic, imaging, and other data to identify new therapies and personalize treatments for patients with neurological and neurodegenerative diseases.
The partners will use Hummingbird's miRNA database and expertise in sample preparation as well as BGI's BGISEQ sequencer and analysis pipeline to develop targeted miRNA IVD assays.
A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.
Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.
In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.
A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.